Browse the corpus

Levodopa/carbidopa/entacapone (LCE) is a type of medication that is used as a combination therapy to address Parkinson disease in patients exhibiting symptoms of motor fluctuations and signs of wearing off while on levodopa/carbidopa. The drug was approved by the U.S. Food and Drug Administration (FDA) in June 2003. Parkinson disease is the second most common neurodegenerative disorder worldwide. The degeneration of the nigrostriatal system in patients with Parkinson disease leads to a diminished synthesis of the neurotransmitter dopamine. LCE falls under the category of dopamine replacement therapy and comprises 3 commonly used ingredients for Parkinson disease—a dopamine precursor (levodopa), an aromatic L-amino acid decarboxylase (AADC) inhibitor (carbidopa), and a catechol-O-methyltransferase (COMT) inhibitor (entacapone). This triple combination treatment enables enhanced and more consistent bioavailability of levodopa in the brain, leading to improved on-time or symptom-free periods for patients. This activity predominantly focuses on the indications, mechanism of action, administration, adverse events, monitoring, and contraindications associated with LCE use. This activity also highlights the role of the interprofessional healthcare team in delivering optimal care for patients dealing with Parkinson disease and its related complexities through the judicious use of LCE. Objectives: Identify patients with Parkinson disease exhibiting motor fluctuations and wearing-off signs for potential levodopa/carbidopa/entacapone combination therapy. Screen patients for contraindications and potential adverse events associated with levodopa/carbidopa/entacapone combination use. Implement appropriate dosing and administration of levodopa/carbidopa/entacapone based on individual patient considerations. Collaborate with neurologists, pharmacists, and other interprofessional healthcare professionals to ensure comprehensive Parkinson disease management for optimal patient outcomes. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose The literature describes only a limited number of cases of LCE toxicity, primarily attributed to dopamine overstimulation. Typical manifestations include altered mental status, hallucinations, other psychiatric symptoms, and cardiovascular disturbances such as tachycardia and hypotension.[24] Management of Overdose In case of suspected overdose, hospitalization is recommended. Rapid initiation of supportive measures, such as oral charcoal and gastric lavage, is necessary to eliminate unabsorbed products from the gastrointestinal tract. Currently, no specific antidote is available for LCE toxicity. When an overdose is suspected, it is advisable to monitor cardiovascular, respiratory, and renal function in a hospital setting. Notably, due to entacapone's high protein binding capacity, hemodialysis is not effective in cases of LCE overdose.

Due to the complex and progressive nature of the condition, treating patients with Parkinson disease necessitates a multidisciplinary healthcare approach.[25] Often, patients are initially started on levodopa/carbidopa by their primary care providers. Early identification of the condition and treatment of patients who need additional therapeutic interventions to address inadequate clinical response, adverse effects, and complications of long-term levodopa/carbidopa therapy is critical for improving care. Therefore, clinical scenarios wherein patients would benefit from transitioning to LCE therapy can enhance compliance, reduce the risk of immediate and long-term complications, and improve the overall quality of life for individuals with Parkinson disease. Comprehensive education for all healthcare team members regarding potential adverse effects, contraindications, and appropriate monitoring for LCE therapy is essential to achieve optimal outcomes and prevent morbidity associated with Parkinson disease and its complications. As per the American Academy of Neurology (AAN) guidelines, LCE can be beneficial for patients experiencing the end-of-dose wearing-off phenomenon.[26] Consultation with neurologists and movement disorder specialists is crucial in the comprehensive management of Parkinson disease. These professionals conduct thorough assessments, considering symptoms and disease progression, to formulate personalized treatment plans. Neurologists play a pivotal role in monitoring motor fluctuations, adjusting pharmacotherapy, and staying abreast of research advancements to ensure optimal care for individuals with Parkinson disease. Pharmacists are critical in performing medication reconciliation and educating patients regarding adverse drug reactions. Nurses contribute by monitoring overall progress to improve compliance. Each member of the interprofessional healthcare team is essential, bringing their unique expertise to deliver comprehensive and effective patient care. Therefore, fostering effective interprofessional communication and care coordination among primary care providers, neurologists, pharmacists, and nurses is crucial. This collaborative approach is essential for enhancing patient safety, minimizing potential errors and delays, and ultimately contributing to improved outcomes for individuals affected by Parkinson disease.